Huang C-T, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503-513.
Baixeras E, Huard B, Miossec C, et al. Characterization of the lymphocyte activation gene 3–encoded
protein: a new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176(2):327-337.
Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during
recurrence of melanoma. J Immunol. 2013;190(9):4899-4909.
Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory
receptors during chronic viral infection. Nat Immunol. 2009;10(1):29-37.
Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4+ CD25high Foxp3+ regulatory
T cells that are expanded at tumor sites. J Immunol. 2010;184(11):6545-6551.
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are
negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A.
2010;107(17):7875-7880.
Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J
Leukoc Biol. 2016;100(2):275-290.
Huang R-Y, Francois A, McGray AJR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and
CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology.
2017. doi:10.1080/2162402X.2016.1249561.
Bottai G, Raschioni C, Losurdo A, et al. An immune stratification reveals a subset of PD-1/LAG-3
double-positive triple-negative breast cancers. Breast Cancer Res. 2016. doi:10.1186/s13058-016-0783-4.